{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,8]],"date-time":"2026-01-08T01:50:30Z","timestamp":1767837030277,"version":"3.49.0"},"reference-count":51,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2022,3,3]],"date-time":"2022-03-03T00:00:00Z","timestamp":1646265600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,3,3]],"date-time":"2022-03-03T00:00:00Z","timestamp":1646265600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100009827","name":"Alexandria University","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100009827","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur J Clin Pharmacol"],"published-print":{"date-parts":[[2022,6]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Purpose<\/jats:title>\n                <jats:p>Heart rate reduction (HR) is a cornerstone in heart failure therapy as it improves patient outcomes. The aim of this study is to evaluate short-term effect of ivabradine on NT-Pro BNP and neopterin in heart failure patients and assess the association between HR and these biomarkers.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>Sixty patients on standard heart failure therapy were randomly allocated into ivabradine group (<jats:italic>n<\/jats:italic>\u2009=\u200930) and non-ivabradine group (<jats:italic>n<\/jats:italic>\u2009=\u200930). Ivabradine 5\u00a0mg twice daily was given for 3\u00a0months. Lipid profile and kidney functions were performed and blood samples for NT-Pro BNP and neopterin were analysed at baseline and after 3\u00a0months of intervention in both groups.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>There was a significant improvement in NYHA class in ivabradine group (<jats:italic>p<\/jats:italic>\u2009&lt;\u20090.001). Ejection fraction was improved in ivabradine and non-ivabradine groups after intervention (<jats:italic>p<\/jats:italic>\u2009&lt;\u20090.001), with a greater improvement in ivabradine group (<jats:italic>p<\/jats:italic>\u2009=\u20090.026). Heart rate was reduced in ivabradine group (<jats:italic>p<\/jats:italic>\u2009&lt;\u20090.001) and non-ivabradine group (<jats:italic>p<\/jats:italic>\u2009&lt;\u20090.001) yet greater reduction was seen in ivabradine group (<jats:italic>p<\/jats:italic>\u2009&lt;\u20090.001). Serum creatinine and blood urea nitrogen were reduced in ivabradine group (Scr: <jats:italic>p<\/jats:italic>\u2009=\u20090.001, BUN: <jats:italic>p<\/jats:italic>\u2009=\u20090.001). NT-Pro BNP and neopterin levels significantly decreased in ivabradine group (NT-Pro BNP: <jats:italic>p<\/jats:italic>\u2009&lt;\u20090.001, neopterin <jats:italic>p<\/jats:italic>\u2009&lt;\u20090.001). Significant positive correlation was found between HR and biomarker levels after intervention (NT-Pro BNP: <jats:italic>r<\/jats:italic>\u2009=\u20090.475, <jats:italic>p<\/jats:italic>\u2009&lt;\u20090.001, neopterin: <jats:italic>r<\/jats:italic>\u2009=\u20090.384, <jats:italic>p<\/jats:italic>\u2009=\u20090.002).<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusion<\/jats:title>\n                <jats:p>Ivabradine therapy reduced levels of both biomarkers which correlated well with HR. Biomarker levels might provide a tool for assessing ivabradine effectiveness in HF.<\/jats:p>\n                <jats:p>Trial registration<\/jats:p>\n                <jats:p>Date: June 26, 2020. Identifier: NCT04448899. Link: Ivabradine in Patients with Congestive Heart Failure\u2014Full Text View\u2014ClinicalTrials.gov.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1007\/s00228-022-03290-6","type":"journal-article","created":{"date-parts":[[2022,3,3]],"date-time":"2022-03-03T07:02:42Z","timestamp":1646290962000},"page":"943-954","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":12,"title":["Clinical comparative study assessing the effect of ivabradine on neopterin and NT-Pro BNP against standard treatment in chronic heart failure patients"],"prefix":"10.1007","volume":"78","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2505-0915","authenticated-orcid":false,"given":"Gaidaa M.","family":"Dogheim","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ibtsam","family":"Khairat","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gamal A.","family":"Omran","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sahar M.","family":"El-Haggar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ahmed M. El","family":"Amrawy","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5983-3993","authenticated-orcid":false,"given":"Rehab H.","family":"Werida","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2022,3,3]]},"reference":[{"issue":"4","key":"3290_CR1","first-page":"403","volume":"51","author":"MS Figueroa","year":"2006","unstructured":"Figueroa MS, Peters JI (2006) Congestive heart failure: diagnosis, pathophysiology, therapy, and implications for respiratory care. Respir Care 51(4):403\u2013412","journal-title":"Respir Care"},{"key":"3290_CR2","doi-asserted-by":"publisher","unstructured":"Azad N, Lemay G (2014) Management of chronic heart failure in the older population.\u00a0J Geriatr Cardiol\u00a011(4):329\u2013337. https:\/\/doi.org\/10.11909\/j.issn.1671-5411.2014.04.008","DOI":"10.11909\/j.issn.1671-5411.2014.04.008"},{"issue":"8","key":"3290_CR3","doi-asserted-by":"publisher","first-page":"968","DOI":"10.1111\/j.1532-5415.1997.tb02968.x","volume":"45","author":"MW Rich","year":"1997","unstructured":"Rich MW (1997) Epidemiology, pathophysiology, and etiology of congestive heart failure in older adults. J Am Geriatr Soc 45(8):968\u2013974. https:\/\/doi.org\/10.1111\/j.1532-5415.1997.tb02968.x","journal-title":"J Am Geriatr Soc"},{"issue":"2","key":"3290_CR4","doi-asserted-by":"publisher","first-page":"180","DOI":"10.4065\/mcp.2009.0494","volume":"85","author":"GV Ramani","year":"2010","unstructured":"Ramani GV, Uber PA, Mehra MR (2010) Chronic heart failure: contemporary diagnosis and management. Mayo Clin Proc 85(2):180\u2013195. https:\/\/doi.org\/10.4065\/mcp.2009.0494","journal-title":"Mayo Clin Proc"},{"key":"3290_CR5","doi-asserted-by":"publisher","unstructured":"Yao YS, Li TD, Zeng ZH (2020) Mechanisms underlying direct actions of hyperlipidemia on myocardium: an updated review.\u00a0Lipids Health Dis 19(1):23. Published 2020 Feb 8. https:\/\/doi.org\/10.1186\/s12944-019-1171-8","DOI":"10.1186\/s12944-019-1171-8"},{"key":"3290_CR6","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1016\/j.addr.2020.07.019","volume":"159","author":"J Soppert","year":"2020","unstructured":"Soppert J, Lehrke M, Marx N, Jankowski J, Noels H (2020) Lipoproteins and lipids in cardiovascular disease: from mechanistic insights to therapeutic targeting. Adv Drug Deliv Rev 159:4\u201333. https:\/\/doi.org\/10.1016\/j.addr.2020.07.019","journal-title":"Adv Drug Deliv Rev"},{"issue":"16","key":"3290_CR7","doi-asserted-by":"publisher","first-page":"e147","DOI":"10.1016\/j.jacc.2013.05.019","volume":"62","author":"CW Yancy","year":"2013","unstructured":"Yancy CW, Jessup M, Bozkurt B et al (2013) 2013 ACCF\/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation\/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol 62(16):e147\u2013e239. https:\/\/doi.org\/10.1016\/j.jacc.2013.05.019","journal-title":"J Am Coll Cardiol"},{"key":"3290_CR8","doi-asserted-by":"publisher","unstructured":"McDonagh TA, Metra M, Adamo M et al (2021) ESC guidelines for the diagnosis and treatment of acute and chronic heart failure [published online ahead of print, 2021 Aug 27].\u00a0Eur Heart J\u00a0;ehab368. https:\/\/doi.org\/10.1093\/eurheartj\/ehab368","DOI":"10.1093\/eurheartj\/ehab368"},{"issue":"2","key":"3290_CR9","doi-asserted-by":"publisher","first-page":"279","DOI":"10.1517\/17425255.2014.876005","volume":"10","author":"GM Rosa","year":"2014","unstructured":"Rosa GM, Ferrero S, Ghione P, Valbusa A, Brunelli C (2014) An evaluation of the pharmacokinetics and pharmacodynamics of ivabradine for the treatment of heart failure. Expert Opin Drug Metab Toxicol 10(2):279\u2013291. https:\/\/doi.org\/10.1517\/17425255.2014.876005","journal-title":"Expert Opin Drug Metab Toxicol"},{"issue":"3","key":"3290_CR10","doi-asserted-by":"publisher","first-page":"497","DOI":"10.1016\/j.amjcard.2013.10.033","volume":"113","author":"JS Borer","year":"2014","unstructured":"Borer JS, B\u00f6hm M, Ford I et al (2014) Efficacy and safety of ivabradine in patients with severe chronic systolic heart failure (from the SHIFT study). Am J Cardiol 113(3):497\u2013503. https:\/\/doi.org\/10.1016\/j.amjcard.2013.10.033","journal-title":"Am J Cardiol"},{"key":"3290_CR11","doi-asserted-by":"publisher","unstructured":"Swedberg K, Komajda M, B\u00f6hm M et al (2010) Ivabradine and outcomes in chronic heart failure (SHIFT): a randomised placebo-controlled study [published correction appears in Lancet\u00a02010 Dec 11;376(9757):1988. Lajnscak, M [corrected to Lainscak, M]; Rabanedo, I Roldan [corrected to Rabad\u00e1n, I Roldan]; Leva, M [corrected to Ieva, M]].\u00a0Lancet\u00a02010;376(9744):875\u2013885. https:\/\/doi.org\/10.1016\/S0140-6736(10)61198-1","DOI":"10.1016\/S0140-6736(10)61198-1"},{"key":"3290_CR12","doi-asserted-by":"publisher","unstructured":"Palazzuoli A, Gallotta M, Quatrini I, Nuti R (2010) Natriuretic peptides (BNP and NT-proBNP): measurement and relevance in heart failure.\u00a0Vasc Health Risk Manag 6:411\u2013418. Published 2010 Jun 1. https:\/\/doi.org\/10.2147\/vhrm.s5789","DOI":"10.2147\/vhrm.s5789"},{"issue":"3","key":"3290_CR13","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1016\/j.ejheart.2004.01.003","volume":"6","author":"M Richards","year":"2004","unstructured":"Richards M, Troughton RW (2004) NT-proBNP in heart failure: therapy decisions and monitoring. Eur J Heart Fail 6(3):351\u2013354. https:\/\/doi.org\/10.1016\/j.ejheart.2004.01.003","journal-title":"Eur J Heart Fail"},{"issue":"3","key":"3290_CR14","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1016\/j.ejheart.2004.01.008","volume":"6","author":"P Bettencourt","year":"2004","unstructured":"Bettencourt P (2004) NT-proBNP and BNP: biomarkers for heart failure management. Eur J Heart Fail 6(3):359\u2013363. https:\/\/doi.org\/10.1016\/j.ejheart.2004.01.008","journal-title":"Eur J Heart Fail"},{"issue":"1","key":"3290_CR15","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1016\/j.ejheart.2003.10.003","volume":"6","author":"LS Nielsen","year":"2004","unstructured":"Nielsen LS, Svanegaard J, Klitgaard NA, Egeblad H (2004) N-terminal pro-brain natriuretic peptide for discriminating between cardiac and non-cardiac dyspnoea. Eur J Heart Fail 6(1):63\u201370. https:\/\/doi.org\/10.1016\/j.ejheart.2003.10.003","journal-title":"Eur J Heart Fail"},{"issue":"1\u20132","key":"3290_CR16","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1016\/j.cccn.2003.10.027","volume":"341","author":"T Mueller","year":"2004","unstructured":"Mueller T, Gegenhuber A, Poelz W, Haltmayer M (2004) Head-to-head comparison of the diagnostic utility of BNP and NT-proBNP in symptomatic and asymptomatic structural heart disease. Clin Chim Acta 341(1\u20132):41\u201348. https:\/\/doi.org\/10.1016\/j.cccn.2003.10.027","journal-title":"Clin Chim Acta"},{"issue":"2","key":"3290_CR17","doi-asserted-by":"publisher","first-page":"68","DOI":"10.4081\/monaldi.2007.454","volume":"68","author":"M Pacileo","year":"2007","unstructured":"Pacileo M, Cirillo P, De Rosa S et al (2007) The role of neopterin in cardiovascular disease. Monaldi Arch Chest Dis 68(2):68\u201373. https:\/\/doi.org\/10.4081\/monaldi.2007.454","journal-title":"Monaldi Arch Chest Dis"},{"issue":"1","key":"3290_CR18","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1016\/j.bbagen.2004.02.007","volume":"1672","author":"JA Razumovitch","year":"2004","unstructured":"Razumovitch JA, Fuchs D, Semenkova GN, Cherenkevich SN (2004) Influence of neopterin on generation of reactive species by myeloperoxidase in human neutrophils. Biochim Biophys Acta 1672(1):46\u201350. https:\/\/doi.org\/10.1016\/j.bbagen.2004.02.007","journal-title":"Biochim Biophys Acta"},{"issue":"4","key":"3290_CR19","doi-asserted-by":"publisher","first-page":"627","DOI":"10.1038\/sj.bjp.0707408","volume":"153","author":"SP Gieseg","year":"2008","unstructured":"Gieseg SP, Crone EM, Flavall EA, Amit Z (2008) Potential to inhibit growth of atherosclerotic plaque development through modulation of macrophage neopterin\/7,8-dihydroneopterin synthesis. Br J Pharmacol 153(4):627\u2013635. https:\/\/doi.org\/10.1038\/sj.bjp.0707408","journal-title":"Br J Pharmacol"},{"issue":"24","key":"3290_CR20","doi-asserted-by":"publisher","first-page":"3071","DOI":"10.1161\/CIRCULATIONAHA.106.666511","volume":"115","author":"KK Ray","year":"2007","unstructured":"Ray KK, Morrow DA, Sabatine MS et al (2007) Long-term prognostic value of neopterin: a novel marker of monocyte activation in patients with acute coronary syndrome. Circulation 115(24):3071\u20133078. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.106.666511","journal-title":"Circulation"},{"issue":"3\u20134","key":"3290_CR21","doi-asserted-by":"publisher","first-page":"307","DOI":"10.3109\/10408369209114604","volume":"29","author":"D Fuchs","year":"1992","unstructured":"Fuchs D, Weiss G, Reibnegger G, Wachter H (1992) The role of neopterin as a monitor of cellular immune activation in transplantation, inflammatory, infectious, and malignant diseases. Crit Rev Clin Lab Sci 29(3\u20134):307\u2013341. https:\/\/doi.org\/10.3109\/10408369209114604","journal-title":"Crit Rev Clin Lab Sci"},{"key":"3290_CR22","unstructured":"Wietlicka-Kokoszanek I, Jablecka A, Smolarek I et al (2010) Neopterin as a prognostic marker in patients with chronic heart failure.\u00a0Med Sci Monit 16(5):CR232-CR237"},{"issue":"3","key":"3290_CR23","doi-asserted-by":"publisher","first-page":"216","DOI":"10.1080\/00015385.2018.1478266","volume":"74","author":"\u015e Demir","year":"2019","unstructured":"Demir \u015e, Ede H, Kaplan M, Yavuz F, Y\u00fccel C, Kurt \u0130H (2019) Neopterin as a novel marker; well correlated with mortality and morbidity in patients with advanced systolic heart failure. Acta Cardiol 74(3):216\u2013221. https:\/\/doi.org\/10.1080\/00015385.2018.1478266","journal-title":"Acta Cardiol"},{"key":"3290_CR24","doi-asserted-by":"publisher","unstructured":"Nadar SK, Shaikh MM (2019) Biomarkers in routine heart failure clinical care.\u00a0Card Fail Rev. 5(1):50\u201356. https:\/\/doi.org\/10.15420\/cfr.2018.27.2","DOI":"10.15420\/cfr.2018.27.2"},{"issue":"5","key":"3290_CR25","doi-asserted-by":"publisher","first-page":"614","DOI":"10.1161\/CIRCRESAHA.118.312706","volume":"123","author":"NE Ibrahim","year":"2018","unstructured":"Ibrahim NE, Januzzi JL Jr (2018) Established and emerging roles of biomarkers in heart failure. Circ Res 123(5):614\u2013629. https:\/\/doi.org\/10.1161\/CIRCRESAHA.118.312706","journal-title":"Circ Res"},{"issue":"2","key":"3290_CR26","doi-asserted-by":"publisher","first-page":"318","DOI":"10.1016\/j.ijcard.2009.11.042","volume":"145","author":"T Sasaki","year":"2010","unstructured":"Sasaki T, Takeishi Y, Suzuki S et al (2010) High serum level of neopterin is a risk factor of patients with heart failure. Int J Cardiol 145(2):318. https:\/\/doi.org\/10.1016\/j.ijcard.2009.11.042","journal-title":"Int J Cardiol"},{"issue":"11","key":"3290_CR27","first-page":"1893","volume":"74","author":"J Doust","year":"2006","unstructured":"Doust J, Lehman R, Glasziou P (2006) The role of BNP testing in heart failure. Am Fam Physician 74(11):1893\u20131898","journal-title":"Am Fam Physician"},{"issue":"6","key":"3290_CR28","doi-asserted-by":"publisher","first-page":"499","DOI":"10.1093\/clinchem\/18.6.499","volume":"18","author":"WT Friedewald","year":"1972","unstructured":"Friedewald WT, Levy RI, Fredrickson DS (1972) Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem 18(6):499\u2013502","journal-title":"Clin Chem"},{"issue":"10","key":"3290_CR29","doi-asserted-by":"publisher","first-page":"967","DOI":"10.1093\/eurheartj\/ehi190","volume":"26","author":"A Diaz","year":"2005","unstructured":"Diaz A, Bourassa MG, Guertin MC, Tardif JC (2005) Long-term prognostic value of resting heart rate in patients with suspected or proven coronary artery disease. Eur Heart J 26(10):967\u2013974. https:\/\/doi.org\/10.1093\/eurheartj\/ehi190","journal-title":"Eur Heart J"},{"issue":"7\u20138","key":"3290_CR30","doi-asserted-by":"publisher","first-page":"637","DOI":"10.1081\/ceh-200031959","volume":"26","author":"P Palatini","year":"2004","unstructured":"Palatini P, Julius S (2004) Elevated heart rate: a major risk factor for cardiovascular disease. Clin Exp Hypertens 26(7\u20138):637\u2013644. https:\/\/doi.org\/10.1081\/ceh-200031959","journal-title":"Clin Exp Hypertens"},{"issue":"16","key":"3290_CR31","doi-asserted-by":"publisher","first-page":"1757","DOI":"10.2165\/00003495-200464160-00003","volume":"64","author":"D DiFrancesco","year":"2004","unstructured":"DiFrancesco D, Camm JA (2004) Heart rate lowering by specific and selective I(f) current inhibition with ivabradine: a new therapeutic perspective in cardiovascular disease. Drugs 64(16):1757\u20131765. https:\/\/doi.org\/10.2165\/00003495-200464160-00003","journal-title":"Drugs"},{"issue":"5","key":"3290_CR32","doi-asserted-by":"publisher","first-page":"553","DOI":"10.1586\/14779072.2016.1165092","volume":"14","author":"C Henri","year":"2016","unstructured":"Henri C, O\u2019Meara E, De Denus S, Elzir L, Tardif JC (2016) Ivabradine for the treatment of chronic heart failure. Expert Rev Cardiovasc Ther 14(5):553\u2013561. https:\/\/doi.org\/10.1586\/14779072.2016.1165092","journal-title":"Expert Rev Cardiovasc Ther"},{"issue":"6","key":"3290_CR33","doi-asserted-by":"publisher","first-page":"550","DOI":"10.1016\/j.ejheart.2008.04.005","volume":"10","author":"GM De Ferrari","year":"2008","unstructured":"De Ferrari GM, Mazzuero A, Agnesina L et al (2008) Favourable effects of heart rate reduction with intravenous administration of ivabradine in patients with advanced heart failure. Eur J Heart Fail 10(6):550\u2013555. https:\/\/doi.org\/10.1016\/j.ejheart.2008.04.005","journal-title":"Eur J Heart Fail"},{"issue":"3","key":"3290_CR34","doi-asserted-by":"publisher","first-page":"234","DOI":"10.1159\/000322905","volume":"117","author":"D Busseuil","year":"2010","unstructured":"Busseuil D, Shi Y, Mecteau M et al (2010) Heart rate reduction by ivabradine reduces diastolic dysfunction and cardiac fibrosis. Cardiology 117(3):234\u2013242. https:\/\/doi.org\/10.1159\/000322905","journal-title":"Cardiology"},{"key":"3290_CR35","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1007\/5584_2017_140","volume":"1067","author":"AE Berezin","year":"2018","unstructured":"Berezin AE (2018) Circulating biomarkers in heart failure. Adv Exp Med Biol 1067:89\u2013108. https:\/\/doi.org\/10.1007\/5584_2017_140","journal-title":"Adv Exp Med Biol"},{"key":"3290_CR36","doi-asserted-by":"publisher","unstructured":"Sargento L, Satendra M, Longo S, Lousada N, Palma dos Reis R (2013) Early NT-proBNP decrease with ivabradine in ambulatory patients with systolic heart failure.\u00a0Clin Cardiol\u00a036(11):677\u2013682. https:\/\/doi.org\/10.1002\/clc.22183","DOI":"10.1002\/clc.22183"},{"issue":"5","key":"3290_CR37","doi-asserted-by":"publisher","first-page":"501","DOI":"10.5603\/CJ.a2015.0012","volume":"22","author":"S Ordu","year":"2015","unstructured":"Ordu S, Yildiz BS, Alihanoglu YI et al (2015) Effects of ivabradine therapy on heart failure biomarkers. Cardiol J 22(5):501\u2013509. https:\/\/doi.org\/10.5603\/CJ.a2015.0012","journal-title":"Cardiol J"},{"issue":"3","key":"3290_CR38","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1016\/j.ejheart.2004.01.010","volume":"6","author":"TA McDonagh","year":"2004","unstructured":"McDonagh TA, Holmer S, Raymond I, Luchner A, Hildebrant P, Dargie HJ (2004) NT-proBNP and the diagnosis of heart failure: a pooled analysis of three European epidemiological studies. Eur J Heart Fail 6(3):269\u2013273. https:\/\/doi.org\/10.1016\/j.ejheart.2004.01.010","journal-title":"Eur J Heart Fail"},{"issue":"1\u20132","key":"3290_CR39","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1016\/j.clinbiochem.2012.10.022","volume":"46","author":"R Caruso","year":"2013","unstructured":"Caruso R, De Chiara B, Campolo J et al (2013) Neopterin levels are independently associated with cardiac remodeling in patients with chronic heart failure. Clin Biochem 46(1\u20132):94\u201398. https:\/\/doi.org\/10.1016\/j.clinbiochem.2012.10.022","journal-title":"Clin Biochem"},{"key":"3290_CR40","doi-asserted-by":"publisher","unstructured":"Lanser L, P\u00f6lzl G, Fuchs D, Weiss G, Kurz K (2019) Neopterin is associated with disease severity and outcome in patients with non-ischaemic heart failure.\u00a0J Clin Med. 8(12):2230. Published 2019 Dec 17. https:\/\/doi.org\/10.3390\/jcm8122230","DOI":"10.3390\/jcm8122230"},{"issue":"12","key":"3290_CR41","doi-asserted-by":"publisher","first-page":"1136","DOI":"10.1161\/01.cir.97.12.1136","volume":"97","author":"P Aukrust","year":"1998","unstructured":"Aukrust P, Ueland T, M\u00fcller F et al (1998) Elevated circulating levels of C-C chemokines in patients with congestive heart failure. Circulation 97(12):1136\u20131143. https:\/\/doi.org\/10.1161\/01.cir.97.12.1136","journal-title":"Circulation"},{"issue":"12","key":"3290_CR42","doi-asserted-by":"publisher","first-page":"1294","DOI":"10.1002\/ejhf.347","volume":"17","author":"M Komajda","year":"2015","unstructured":"Komajda M, Tavazzi L, Francq BG et al (2015) Efficacy and safety of ivabradine in patients with chronic systolic heart failure and diabetes: an analysis from the SHIFT trial. Eur J Heart Fail 17(12):1294\u20131301. https:\/\/doi.org\/10.1002\/ejhf.347","journal-title":"Eur J Heart Fail"},{"issue":"14","key":"3290_CR43","doi-asserted-by":"publisher","first-page":"1569","DOI":"10.1007\/s40265-013-0117-0","volume":"73","author":"P Deedwania","year":"2013","unstructured":"Deedwania P (2013) Selective and specific inhibition of If with ivabradine for the treatment of coronary artery disease or heart failure. Drugs 73(14):1569\u20131586. https:\/\/doi.org\/10.1007\/s40265-013-0117-0","journal-title":"Drugs"},{"issue":"6","key":"3290_CR44","doi-asserted-by":"publisher","first-page":"1443","DOI":"10.1007\/s11096-018-0715-8","volume":"40","author":"C Hartmann","year":"2018","unstructured":"Hartmann C, Bosch NL, de Arag\u00e3o ML, Tierie E, Zytinski L, Baena CP (2018) The effect of ivabradine therapy on heart failure patients with reduced ejection fraction: a systematic review and meta-analysis. Int J Clin Pharm 40(6):1443\u20131453. https:\/\/doi.org\/10.1007\/s11096-018-0715-8","journal-title":"Int J Clin Pharm"},{"issue":"3","key":"3290_CR45","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1007\/s12325-018-0681-5","volume":"35","author":"M Glezer","year":"2018","unstructured":"Glezer M, Vasyuk Y, Karpov Y (2018) Efficacy of ivabradine in combination with beta-blockers versus uptitration of beta-blockers in patients with stable angina (CONTROL-2 Study). Adv Ther 35(3):341\u2013352. https:\/\/doi.org\/10.1007\/s12325-018-0681-5","journal-title":"Adv Ther"},{"issue":"19","key":"3290_CR46","doi-asserted-by":"publisher","first-page":"1506","DOI":"10.1136\/heartjnl-2014-305482","volume":"100","author":"RI Martin","year":"2014","unstructured":"Martin RI, Pogoryelova O, Koref MS, Bourke JP, Teare MD, Keavney BD (2014) Atrial fibrillation associated with ivabradine treatment: meta-analysis of randomised controlled trials. Heart 100(19):1506\u20131510. https:\/\/doi.org\/10.1136\/heartjnl-2014-305482","journal-title":"Heart"},{"key":"3290_CR47","doi-asserted-by":"publisher","unstructured":"DiFrancesco D (2015) HCN4, sinus bradycardia and atrial fibrillation.\u00a0Arrhythm Electrophysiol Rev\u00a04(1):9\u201313. https:\/\/doi.org\/10.15420\/aer.2015.4.1.9","DOI":"10.15420\/aer.2015.4.1.9"},{"key":"3290_CR48","doi-asserted-by":"publisher","unstructured":"Scicchitano P, Carbonara S, Ricci G et al (2012) HCN channels and heart rate.\u00a0Molecules\u00a017(4):4225\u20134235. Published 2012 Apr 5. https:\/\/doi.org\/10.3390\/molecules17044225.","DOI":"10.3390\/molecules17044225"},{"key":"3290_CR49","doi-asserted-by":"publisher","unstructured":"Chobanyan-J\u00fcrgens K, Heusser K, Duncker D et al (2018) Cardiac pacemaker channel (HCN4) inhibition and atrial arrhythmogenesis after releasing cardiac sympathetic activation.\u00a0Sci Rep 8(1):7748. Published 2018 May 17. https:\/\/doi.org\/10.1038\/s41598-018-26099-9","DOI":"10.1038\/s41598-018-26099-9"},{"issue":"11","key":"3290_CR50","doi-asserted-by":"publisher","first-page":"4754","DOI":"10.1167\/iovs.17-21572","volume":"58","author":"S Bemme","year":"2017","unstructured":"Bemme S, Weick M, Gollisch T (2017) Differential effects of HCN channel block on on and off pathways in the retina as a potential cause for medication-induced phosphene perception. Invest Ophthalmol Vis Sci 58(11):4754\u20134767. https:\/\/doi.org\/10.1167\/iovs.17-21572","journal-title":"Invest Ophthalmol Vis Sci"},{"issue":"2","key":"3290_CR51","doi-asserted-by":"publisher","first-page":"1016","DOI":"10.1167\/iovs.09-3680","volume":"51","author":"L Della Santina","year":"2010","unstructured":"Della Santina L, Bouly M, Asta A, Demontis GC, Cervetto L, Gargini C (2010) Effect of HCN channel inhibition on retinal morphology and function in normal and dystrophic rodents. Invest Ophthalmol Vis Sci 51(2):1016\u20131023. https:\/\/doi.org\/10.1167\/iovs.09-3680","journal-title":"Invest Ophthalmol Vis Sci"}],"container-title":["European Journal of Clinical Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00228-022-03290-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00228-022-03290-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00228-022-03290-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,5,14]],"date-time":"2022-05-14T08:05:37Z","timestamp":1652515537000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00228-022-03290-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,3,3]]},"references-count":51,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2022,6]]}},"alternative-id":["3290"],"URL":"https:\/\/doi.org\/10.1007\/s00228-022-03290-6","relation":{},"ISSN":["0031-6970","1432-1041"],"issn-type":[{"value":"0031-6970","type":"print"},{"value":"1432-1041","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,3,3]]},"assertion":[{"value":"6 December 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 February 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 March 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study was done according to the Declaration of Helsinki. Approval was obtained from Research Ethics Committee of Faculty of Pharmacy, Damanhour University (No. 420PP25), and the trial was registered on clinicaltrial.gov by NCT04448899.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"All participants have agreed to be included in this clinical study and provided a written informed consent.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}